CEO, directors depart as Bio21 changes direction
03 June, 2002 by Tanya HollisThe chief executive officer and three other directors have resigned from Bio21 following a restructure that has seen the company abandon its commercial focus.
Signs of new life at Vita Life
31 May, 2002 by Tanya HollisTroubled biopharmaceutical group Vita Life Sciences has warned shareholders not to expect much from the natural medicines arm of its business in the coming year.
Academy admits ARC head Sara
31 May, 2002 by Daniella GoldbergAustralian Research Council CEO Prof Vicki Sara has been admitted by special election as a fellow of the Australian Academy of Science, for her contribution to recent government reforms and initiatives.
Biotech stocks will keep falling... but not too far
30 May, 2002 by Daniella GoldbergAustralian biotechnology companies may be heading for a further tumble, delegates at the Financing Biotechnology meeting in Sydney this week were told.
Prana aims for Nasdaq
29 May, 2002 by Pete YoungPrana Biotechnology is following up recent successful Phase II clinical trials of its therapy for age-related diseases such as Alzheimer's with a bid to list on the US Nasdaq.
Premier makes a cautious ASX debut
29 May, 2002 by Tanya HollisPremier Bionics made a quiet entry to a cautious biotech market today when it listed on the Australian Stock Exchange.
ACT feature: The small territory with big ideas
29 May, 2002 by Melissa TrudingerThe Australian Capital Territory (ACT) has two big advantages when it comes to biotechnology: world-class scientists and its proximity to the Federal government.
WA feature: Miners digging for biotech
28 May, 2002 by Pete YoungBiotech companies and WA's bedrock industry - mining - appear to have little in common.
WA feature: Could biotech be the west's next gold rush?
28 May, 2002 by Pete YoungWestern Australia's bio-industry faces more than its share of hurdles. It is isolated by geography, limited by population and dependent on a State government focussed on traditional resources and agriculture sectors.
Eleventh hour resolution for Amrad
28 May, 2002 by Tanya HollisAn air of disappointment hung over the handful of Amrad shareholders who turned up to what was supposed to be an extraordinary general meeting on May 22.
IDT buys clinical trials research unit
27 May, 2002 by Tanya HollisContract research group Institute of Drug Technology Australia (ASX: IDT) has purchased a clinical trials research unit in a deal the company said will bolster its annual revenue by 20 per cent.
AusBiotech calls for action on R&D Start
27 May, 2002 by Tanya HollisPeak biotechnology industry organisation AusBiotech will urge the Federal government to announce the future of the R&D Start scheme on July 1.
From virtual to functional: ES Cell opens new lab
24 May, 2002 by Tanya HollisGreater collaborative research opportunities are expected to result from the formal opening today of ES Cell International's new Australian research and development facility.
Researchers fume as facility funding lags
24 May, 2002 by Pete YoungFrustration is mounting for bioscience research facilities facing delays in grants promised under the $150 million Major National Research Facility scheme.
Gradipore names new CEO
23 May, 2002 by Iain ScottSydney separation technology specialist Gradipore has appointed Robert Lieb as its new global CEO and vice-chairman.
